Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2010 1
2011 3
2012 2
2013 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. Among authors: hamlett a. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells.
Gresle MM, Jordan MA, Stankovich J, Spelman T, Johnson LJ, Laverick L, Hamlett A, Smith LD, Jokubaitis VG, Baker J, Haartsen J, Taylor B, Charlesworth J, Bahlo M, Speed TP, Brown MA, Field J, Baxter AG, Butzkueven H. Gresle MM, et al. Among authors: hamlett a. Life Sci Alliance. 2020 Jun 9;3(7):e202000650. doi: 10.26508/lsa.202000650. Print 2020 Jul. Life Sci Alliance. 2020. PMID: 32518073 Free PMC article.
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group. Rammohan K, et al. Among authors: hamlett a. Mult Scler Relat Disord. 2012 Jan;1(1):49-54. doi: 10.1016/j.msard.2011.08.006. Epub 2011 Sep 15. Mult Scler Relat Disord. 2012. PMID: 25876451
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ. Comi G, et al. Among authors: hamlett ac. J Neurol. 2013 Apr;260(4):1136-46. doi: 10.1007/s00415-012-6775-0. Epub 2012 Dec 21. J Neurol. 2013. PMID: 23263473 Clinical Trial.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group. Cook S, et al. Among authors: hamlett a. Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228029 Clinical Trial.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group. Giovannoni G, et al. Among authors: hamlett a. Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0. Lancet Neurol. 2011. PMID: 21397565